Please Wait
Applying Filters...
menu
    • menu
    Farmak works in the development, production and marketing of APIs, Intermediates & Specialties// FDA inspected.

    Virtual Booth

    Contact Supplier

    Evonik

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    Quotient Sciences- Molecule to Cure. Fast.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    jdmfs-not-supported-m-2025-04-28

    Virtual Booth

    An Enquiry

    Menu

    Evenamide

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Newron & Myung In Pharm Announce Agreement for evenamide in Korea
    Newron & Myung In Pharm Announce Agreement for evenamide in Korea

    09 Jan 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250109233767/en

    BUSINESSWIRE
    09 Jan 2025
    Share Share
    Newron presents H1 2024 results and provides business update
    Newron presents H1 2024 results and provides business update

    19 Sep 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240919982611/en

    BUSINESSWIRE
    19 Sep 2024
    Share Share
    Newron schizophrenia add-on improves positive, negative symptoms
    Newron schizophrenia add-on improves positive, negative symptoms

    30 Apr 2024

    // Annalee Armstrong FIERCE BIOTECH

    https://www.fiercebiotech.com/ai-and-machine-learning/newrons-schizophrenia-add-improves-symptoms-charging-case-phase-3-test

    Annalee Armstrong FIERCE BIOTECH
    30 Apr 2024
    Share Share
    Data from Newron’s Study and An Evenamide Clinical Outlook Presented at The SIRS
    Data from Newron’s Study and An Evenamide Clinical Outlook Presented at The SIRS

    08 Apr 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240408718700/en

    BUSINESSWIRE
    08 Apr 2024
    Share Share
    Newron Reports Exceptional One-year Results of Study 014/15 With Evenamide
    Newron Reports Exceptional One-year Results of Study 014/15 With Evenamide

    04 Jan 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240104787993/en

    BUSINESSWIRE
    04 Jan 2024
    Share Share
    Newron Completes Enrollment of Schizophrenia Patients in Study 008A
    Newron Completes Enrollment of Schizophrenia Patients in Study 008A

    29 Dec 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20231229998281/en

    BUSINESSWIRE
    29 Dec 2023
    Share Share